PSNL

What is the forward-looking guidance for revenue and earnings in the next quarter and FY 2025?

Created August 06, 2025 at 07:37 PM

Answer

The press release you quoted reports Personalis’ Q2 2025 results (clinical‑test volume, sequential growth, etc.) but it does not include the company’s forward‑looking guidance for the next quarter (Q3 2025) or for the full‑year FY 2025.

In other words, based solely on the information you provided, there is no disclosed guidance on:

Projected revenue for the next quarter (Q3 2025)
Projected earnings (net income or adjusted EBITDA) for the next quarter
Projected total revenue for FY 2025
Projected earnings for FY 2025

If you need those figures, you would have to locate the complete Personalis Q2 2025 earnings release (or a related investor‑presentation/press‑release) where the company typically includes its outlook for the upcoming quarter and the full‑year. Those documents are usually posted on Personalis’ investor‑relations website or on the Business Wire release in its entirety.

Other Questions About This News

What is the net revenue growth rate year-over-year for Q2 2025 and how does it compare to analyst expectations? What is the contribution margin and overall profitability of the NeXT Personal® platform in Q2 2025? What were the underlying drivers of the increase in clinical test volume (e.g., new contracts, pricing changes, new product adoption)? How does the Q2 2025 cash burn and cash runway compare to prior quarters and what is the updated cash runway outlook? How does the 59% sequential increase in clinical tests compare to prior quarters and to the company's historical growth rates? How have recent macro‑economic factors (e.g., reimbursement policy changes, healthcare spending trends) impacted the outlook? What is the expected impact of potential dilution from future equity issuances or convertible debt? What technical or competitive risks could affect the sustainability of the 59% test volume growth? What is the status of the “Win‑in‑MRD” strategy and its potential impact on future market share and pricing power? Are there any regulatory approvals, FDA clearances or reimbursement updates that could affect future revenue? How does Personalis’ performance compare with other precision oncology and genomics companies (e.g., Illumina, Guardant Health, Invitae) in terms of test volume and revenue growth? What are the trends in operating expenses, R&D and SG&A, and how are they impacting profitability? What guidance does management provide regarding the timeline and scalability of the NeXT Personal® platform? What is the composition of the customer base (e.g., number of hospital/clinical partners) and its concentration risk? What are the anticipated impacts of any recent partnership or licensing agreements on future revenue and margins? What is the current level of GAAP and non‑GAAP earnings per share, and how do they compare to consensus estimates?